A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus docetaxel in patients with previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Borghaei, Hossein
Lynch, Thomas James
Rizvi, Naiyer A.
Chow, Laura Quan Man
Reilly, Robert
Crino, Lucio
Buyse, Marc E.
Ezzeddine, Rana
Lestini, Brian Joseph
Brahmer, Julie R.
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[2] Yale Univ, Sch Med, New Haven, CT USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Univ Washington, Seattle, WA 98195 USA
[5] St Mary Hosp, Langhorne, PA USA
[6] Azienda Osped Perugia, Perugia, Italy
[7] Int Inst Drug Dev, Louvain, Belgium
[8] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[9] Bristol Myers Squibb Co, Princeton, NJ USA
[10] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8122
引用
收藏
页数：2
相关论文
共 50 条
  • [21] NIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN COMBINATION WITH PLATINUM-BASED DOUBLET CHEMOTHERAPY (PT-DC) OR ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Antonia, Scott J.
    Rizvi, Naiyer A.
    Chow, Laura Q.
    Borghaei, Hossein
    Brahmer, Julie R.
    Juergens, Rosalyn
    Shepherd, Frances A.
    Laurie, Scott A.
    Gerber, David E.
    Goldman, Jonathan
    Shen, Yun
    Harbison, Christopher
    Chen, Allen C.
    Gettinger, Scott
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S153 - S153
  • [22] Phase 2 study of Nivolumab (Anti-PD-1; ONO-4538/BMS-936558) in Japanese patients with advanced melanoma: Preliminary report
    Yamazaki, N.
    Kiyohara, Y.
    Uhara, H.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S110 - S110
  • [23] Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
    Amin, Asim
    Plimack, Elizabeth R.
    Infante, Jeffrey R.
    Ernstoff, Marc S.
    Rini, Brian I.
    McDermott, David F.
    Knox, Jennifer J.
    Pal, Sumanta Kumar
    Voss, Martin Henner
    Sharma, Padmanee
    Kollmannsberger, Christian K.
    Heng, Daniel Yick Chin
    Spratlin, Jennifer L.
    Shen, Yun
    Kurland, John F.
    Gagnier, Paul
    Hammers, Hans J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status
    Rizvi, N. A.
    Shepherd, F. A.
    Antonia, S. J.
    Brahmer, J. R.
    Chow, L. Q.
    Goldman, J.
    Juergens, R.
    Borghaei, H.
    Ready, N. E.
    Gerber, D. E.
    Shen, Y.
    Harbison, C.
    Chen, A. C.
    Gettinger, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S31 - S31
  • [25] Safety and Response With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (Pts) With Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced Non-Small Cell Lung Cancer (NSCLC)
    Gettinger, S.
    Chow, L. Q.
    Borghaei, H.
    Shen, Y.
    Harbison, C.
    Chen, A. C.
    Rizvi, N. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S34 - S35
  • [26] A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL).
    Robert, Caroline
    Ascierto, Paolo Antonio
    Maio, Michele
    Hernberg, Micaela
    Schmidt, Henrik
    Waxman, Ian
    Garbe, Claus
    Lebbe, Celeste
    Hauschild, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab.
    Callahan, Margaret K.
    Horak, Christine E.
    Curran, Michael A.
    Hollman, Travis
    Schaer, David A.
    Yuan, Jianda
    Lesokhin, Alexander M.
    Kitano, Shigehisa
    Hong, Quan
    Ariyan, Charlotte Eielson
    Busam, Klaus J.
    Feely, William
    Jure-Kunkel, Maria
    Grosso, Joseph
    Simon, Jason S.
    Korman, Alan J.
    Wigginton, Jon M.
    Gupta, Ashok Kumar
    Sznol, Mario
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [28] A phase I study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in combination with sunitinib, pazopanib, or ipilimumab in patients (pts) with metastatic renal cell carcinoma (mRCC).
    Amin, Asirn
    Ernstoff, Marc S.
    Infante, Jeffrey R.
    Heng, Daniel Yick Chin
    Rini, Brian I.
    Plimack, Elizabeth R.
    McDermott, David F.
    Kollmannsberger, Christian K.
    Reaume, Martin Neil
    Spratlin, Jennifer L.
    Knox, Jennifer J.
    Voss, Martin Henner
    Pal, Sumanta Kumar
    Shen, Yuri
    Dhar, Arindarn
    Hammers, Hans J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] An exploratory study of the biologic effects of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) treatment in patients (pts) with advanced (unresectable or metastatic) melanoma (MEL)
    Sosman, Jeffrey Alan
    Martin-Algarra, Salvador
    Wolchok, Jedd D.
    Sharfman, William Howard
    Bhatia, Shailender
    Hodi, F. Stephen
    Hwu, Wen-Jen
    Gajewski, Thomas
    Slingluff, Craig L.
    Kaufman, Howard
    Gupta, Manish
    McGirr, Analia
    Horak, Christine E.
    Ahlers, Christoph Matthias
    Wigginton, Jon M.
    Urba, Walter John
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [30] Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results.
    Antonia, Scott Joseph
    Gettinger, Scott N.
    Chow, Laura Quan Man
    Juergens, Rosalyn A.
    Borghaei, Hossein
    Shen, Yun
    Harbison, Christopher
    Chen, Allen C.
    Ready, Neal
    Rizvi, Naiyer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345